← Back to Search
Co-delivery Of SiRNA And An Anticancer Drug For Treatment Of Multidrug-resistant Cancer.
M. Saad, O. Garbuzenko, T. Minko
Published 2008 · Medicine, Materials Science
Download PDFAnalyze on Scholarcy
AIMS To develop a novel nanomedicine approach for the treatment of multidrug-resistant (MDR) cancer by combining an anticancer drug and suppressors of cellular resistance within one multifunctional nanocarrier-based delivery system (NDS). MATERIALS & METHODS The NDS consisted of cationic liposomes (carrier, 100-140 nm), doxorubicin (DOX, anticancer drug), siRNA targeted to MRP1 and BCL2 mRNA (suppressors of pump and nonpump cellular-resistance, respectively). The resulting approximately 500 nm complex has a zeta potential of +4 mV. RESULTS & DISCUSSION The NDS provides an effective co-delivery of DOX and siRNA as well as cell-death induction and suppression of cellular resistance in MDR lung cancer cells. CONCLUSION We demonstrate NDS-enhanced efficiency of chemotherapy to a level that cannot be achieved by applying its components separately.
This paper references
Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
D. E. Lopes de Menezes (2000)
In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug.
R. I. Pakunlu (2006)
Dysregulation of apoptosis in cancer.
John Calvin Reed (1998)
Apoptosis in cancer.
S. Lowe (2000)
DOTAP/UDCA vesicles: novel approach in oligonucleotide delivery.
B. Ruozi (2007)
The Bcl-2 protein family: arbiters of cell survival.
J. Adams (1998)
Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids
R. Mahato (2009)
Nonviral gene delivery.
H. Akita (2008)
Molecular targeting of drug delivery systems to cancer.
T. Minko (2004)
Comparison of the Anticancer Effect of Free and HPMA Copolymer-Bound Adriamycin in Human Ovarian Carcinoma Cells
T. Minko (2004)
New generation of liposomal drugs for cancer.
T. Minko (2006)
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death
Zoltán N. Oltval (1993)
Targeted Proapoptotic LHRH-BH3 Peptide
S. Dharap (2004)
Multifunctional Nanotherapeutics for Cancer
T. Minko (2008)
Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferrin liposomes: effect of adriamycin ADR-to-lipid ratio.
L. A. Lopez-Barcons (2005)
Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery.
M. L. Patil (2008)
Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer.
S. Kassim (1999)
Polymer-drug conjugates: Progress in polymeric prodrugs
J. Khandare (2006)
Regulation of apoptosis by BH3 domains in a cell-free system
S. Cosulich (1997)
Novel Polymeric Prodrug with Multivalent Components for Cancer Therapy
J. Khandare (2006)
Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer.
J. Kigawa (1998)
Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense.
T. Minko (2003)
In vivo transfection rat small intestine K-cell with pGIP/Ins plasmid by DOTAP liposome
A. Palizban (2007)
JNK1 as a molecular target to limit cellular mortality under hypoxia.
S. Betigeri (2006)
An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy.
K. Takara (2006)
Functional comparison of single- and double-stranded mdr1 antisense oligodeoxynucleotides in human ovarian cancer cell lines.
V. Jekerle (2005)
Polymeric nanoparticles for cancer therapy
S. Parveen (2008)
Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides.
S. Dharap (2003)
Strategies for in vivo siRNA delivery in cancer.
A. Sanguino (2008)
Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line.
T. Minko (1999)
Targeted proapoptotic anticancer drug delivery system.
P. Chandna (2007)
Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme.
H. Hatanaka (2001)
Multidrug resistance in non-small-cell lung cancer.
G. Scagliotti (1999)
Mechanisms of cellular drug resistance and strategies to overcome it
T. Minko (2004)
Cationic lipids enhance siRNA-mediated interferon response in mice.
Z. Ma (2005)
Simultaneous Modulation of Multidrug Resistance and Antiapoptotic Cellular Defense by MDR1 and BCL-2 Targeted Antisense Oligonucleotides Enhances the Anticancer Efficacy of Doxorubicin
R. I. Pakunlu (2004)
BCL-2 family members and the mitochondria in apoptosis.
A. Gross (1999)
Targeted proapoptotic 17 LHRH - BH 3 peptide
SS Dharap (2003)
A fast and sensitive method for measuring the integrity of siRNA-carrier complexes in full human serum.
K. Buyens (2008)
Enhancement of the Efficacy of Chemotherapy for Lung Cancer by Simultaneous Suppression of Multidrug Resistance and Antiapoptotic Cellular Defense
R. I. Pakunlu (2004)
Modulation of thyroid hormone receptor silencing function by co-repressors and a synergizing transcription factor.
M. Lutz (2000)
Polymeric 33 drugs
T Minko (2005)
Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?
M. Saad (2008)
Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.
S. Dharap (2005)
RNA-interference effectors and their delivery.
D. Putnam (2006)
Molecular Targeting of BCL2 and BCLXL Proteins by Synthetic BCL2 Homology 3 Domain Peptide Enhances the Efficacy of Chemotherapy
S. Dharap (2006)
Particulate systems as adjuvants and carriers for peptide and protein antigens.
M. Liang (2006)
Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs.
A. Aszalos (1998)
Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells.
Hao Wu (2003)
Jasmonates in cancer therapy.
E. Flescher (2007)
Bak BH3 Peptides Antagonize Bcl-xL Function and Induce Apoptosis through Cytochrome c-independent Activation of Caspases*
E. P. Holinger (1999)
Glutamyl Cysteine Synthetase UpRegulates Glutathione and Multidrug Resistance-associated Protein in Patients with Chemoresistant Epithelial Ovarian Cancer
Delivery of Small Interfering RNA. A Review and an Example of Application to a Junction Oncogene
Anne-Laure Ramon (2008)
Multidrug resistance‐associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate
L. Homolya (2003)
Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins.
R. Lutz (2000)
Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1
R. Watts (2006)
Small Interfering RNA-induced Suppression of MDR 1 ( P-Glycoprotein ) Restores Sensitivity to Multidrug-resistant Cancer Cells 1
Hao Wu (2003)
Nonviral Nanoscale-Based Delivery of Antisense Oligonucleotides Targeted to Hypoxia-Inducible Factor 1α Enhances the Efficacy of Chemotherapy in Drug-Resistant Tumor
Y. Wang (2008)
Nonviral gene 52 delivery
H Akita (2000)
Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase.
J. Zhou (2006)
Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.
D. E. Lopes de Menezes (2003)
Relationship Between Chemotherapy Response of Small Cell Lung Cancer and P-glycoprotein or Multidrug Resistance-Related Protein Expression
T.-C. Hsia (2002)
Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
M. Ihnat (1999)
Targeted delivery of small interfering RNA: approaching effective cancer therapies.
K. Pirollo (2008)
Glutathione Export during Apoptosis Requires Functional Multidrug Resistance-associated Proteins*
C. Hammond (2007)
Advances in cancer gene therapy: tumor-targeted delivery of therapeutic pDNA, siRNA, and dsRNA nucleic acids.
E. Wagner (2007)
Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility.
A. Schroeder (2007)
Role of Cholesterol, DOTAP, and DPPC in Prostasome/Spermatozoa Interaction and Fusion
C. Palmerini (2006)
This paper is referenced by
A multifunctional persistent luminescent nanoprobe for imaging guided dual-stimulus responsive and triple-synergistic therapy of drug resistant tumor cells.
Fengxia Su (2019)
Role of therapeutic agents on repolarisation of tumour-associated macrophage to halt lung cancer progression
Hibah M Aldawsari (2019)
Nano-Platforms for Tumor-Targeted Delivery of Nucleic Acid Therapies
Arun K Iyer (2014)
Nanoparticles for gene delivery.
H. Tian (2013)
Nanocarriers for the simultaneous co-delivery of therapeutic genes and anticancer drugs.
N. Choudhury (2012)
Co-delivery of protein and small molecule therapeutics using nanoparticle-stabilized nanocapsules.
C. S. Kim (2015)
Nanocarriers for siRNA delivery to overcome cancer multidrug resistance
Qingshuo Meng (2013)
PEGylated polymer micelles for anticancer drug delivery carrier
Masao Kamimura (2014)
pH-sensitive CAP/SiO2 composite for efficient co-delivery of doxorubicin and siRNA to overcome multiple drug resistance
Zheng Cai (2020)
Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance
Yinghuan Li (2019)
Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense.
M. Sun (2015)
Co-delivery of small interfering RNA using a camptothecin prodrug as the carrier.
Qiong Tang (2014)
Co-delivery of anti-PLK-1 siRNA and camptothecin by nanometric polydiacetylenic micelles results in a synergistic cell killing
Manon Ripoll (2018)
Supramolecular assemblies in functional siRNA delivery: where do we stand?
Hamidreza M. Aliabadi (2012)
Combination Approach: the Future of the War Against Cancer
L. Chen (2015)
Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers
O. Garbuzenko (2019)
Nanoformulations for combination or cascade anticancer therapy.
L. Miao (2017)
Cholesterol Derivatives Based Charged Liposomes for Doxorubicin Delivery: Preparation, In Vitro and In Vivo Characterization
Yu Nie (2012)
Multifunctional Natural Material-based Delivery Systems for Gene Therapy
Qiong Tang (2014)
pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells
H. Chen (2015)
Lipid nanoparticles as non-viral vectors for siRNA delivery
R. Petrilli (2016)
Biomaterials in Regenerative Medicine and the Immune System
L. Santambrogio (2015)
Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease
O. Simmons (2012)
Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention
O. Garbuzenko (2014)
Nanopreparations to overcome multidrug resistance in cancer.
N. Patel (2013)
Nanoparticle-assisted combination therapies for effective cancer treatment.
C. Hu (2010)
Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles.
Qiaoya Lin (2012)
The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
Nuo Cao (2011)
Intracellular delivery of antisense peptide nucleic acid by fluorescent mesoporous silica nanoparticles.
Xing Ma (2014)
Synergism through combination of chemotherapy and oxidative stress-induced autophagy in A549 lung cancer cells using redox-responsive nanohybrids: a new strategy for cancer therapy.
Hsin-Yi Lu (2015)
Enhanced cytotoxicity by a benzothiazole-containing cisplatin derivative in breast cancer cells
Chaoqun You (2017)
LHRH-targeted nanoparticles for cancer therapeutics.
T. Minko (2010)See more